Muzumbukilwa Tambwe Willy, Manimani Riziki Ghislain, Mushebenge Aganze Gloire-Aime, Vagiri Rajesh Vikram, Nlooto Manimbulu
Department of Pharmaceutical Sciences, Discipline of Pharmaceutical Sciences, School of Health Sciences, Westville Campus, University of KwaZulu-Natal, University Road, Durban 4001, South Africa.
Department of Internal Medicine, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban 4001, South Africa.
AIDS Res Treat. 2024 Dec 10;2024:8834740. doi: 10.1155/arat/8834740. eCollection 2024.
Despite access to antiretroviral therapy (ART), South Africa has a high human immunodeficiency virus (HIV) burden. Treatment outcomes among individuals on highly active ART (HAART) in KwaZulu-Natal, with a higher incidence of HIV, are not fully known. This study evaluated the impact of HAART outcomes and identified and analyzed the factors associated with the outcomes in people living with HIV and AIDS (PLWHA) in the high-incidence region of KwaZulu-Natal Province, South Africa. This retrospective medical record review was conducted at King Edward VIII Hospital in South Africa. Data analysis was performed using STATA software Version 18.0 and Microsoft Excel 2021. The estimates used were 95% confidence intervals, and a value < 0.05 was considered statistically significant. A total of 707 clinical records of PLWHA were examined and analyzed; less than half of them (44.98%, = 318) achieved the benchmark of two consecutive instances of suppressed viral loads. The CD4 greater than or equal to 500 cells/mm at baseline average of 22.91% ( = 162) registered an increase to 48.94% ( = 346) in the 6 month and further escalated to 79.49% ( = 562) by the 12 month following ART initiation. A total of 160 deaths (mortality rate of 22.63%) were recorded within the study period. The percentage of HIV-infected patients attaining viral suppression at 6 and 12 months after initiating the treatment was respectively 44.98% and 67.04%, below the 90% target established by the Joint United Nations Program on HIV/AIDS (UNAIDS). The proportion of favorable immunological responses for individuals on ART increased over time.
尽管可以获得抗逆转录病毒疗法（ART），但南非的人类免疫缺陷病毒（HIV）负担仍然很高。夸祖鲁-纳塔尔省的HIV发病率较高，接受高效抗逆转录病毒疗法（HAART）的个体的治疗结果尚不完全清楚。本研究评估了HAART结果的影响，并确定和分析了南非夸祖鲁-纳塔尔省高发病率地区艾滋病毒和艾滋病患者（PLWHA）中与结果相关的因素。这项回顾性病历审查在南非爱德华八世国王医院进行。使用STATA软件18.0版和Microsoft Excel 2021进行数据分析。所使用的估计值为95%置信区间，P值<0.05被认为具有统计学意义。共检查和分析了707份PLWHA的临床记录；其中不到一半（44.98%，n = 318）达到了连续两次病毒载量被抑制的基准。基线时CD4大于或等于500个细胞/mm³的平均比例为22.91%（n = 162），在开始ART后的6个月增加到48.94%（n = 346），并在12个月时进一步升至79.49%（n = 562）。在研究期间共记录了160例死亡（死亡率为22.63%）。开始治疗后6个月和12个月达到病毒抑制的HIV感染患者百分比分别为44.98%和67.04%，低于联合国艾滋病规划署（UNAIDS）设定的90%目标。接受ART治疗的个体的良好免疫反应比例随时间增加。
